BioCentury
ARTICLE | Clinical News

Fruquintinib: Phase II started

June 9, 2014 7:00 AM UTC

Hutchison China MediTech began a double-blind, placebo-controlled, Chinese Phase II trial to compare fruquintinib vs. best supportive care (BSC) in about 90 non-squamous NSCLC patients who have failed...